L3VLUP
ProSign in

RCEL in the 13F filings

Avita Therapeutics Inc · CUSIP 05380C102

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Surgical, medical and electromedical devices
Quarter
Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020
Quarter end
31 Dec 2020
the date the book describes
Filed
16 Feb 2021
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
91
filed both Q3 2020 and Q4 2020; 0 listed it in both
Shares listed
138,760
combined, among listed positions
Reported value
$2.6m
combined, at the quarter end

Managers listing RCEL in Q4 2020

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2020, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
ExodusPoint Capital Management LP138,760$2.6munder 0.1%Newnew16 Feb 2021 (the filing on sec.gov)

Largest increases and reductions, by shares

There is no earlier quarter on file to compare with.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
1 in Q4 2020 to 1 in Q2 2022

Tracked managers listing it, at least.

00111Q4 2020Q1 2021Q2 2021Q3 2021Q4 2021Q1 2022Q2 2022
the quarter shown share splitClick a quarter to open it.
RCEL by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20201$2.6mn.a.n.a.
Q1 20211$16mn.a.n.a.
Q2 20211$16mn.a.n.a.
Q3 20211$14mn.a.n.a.
Q4 20211$9.6mn.a.n.a.
Q1 20221$6.8mn.a.n.a.
Q2 20221$2.8mn.a.n.a.

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

RCEL and LLY →RCEL and JNJ →RCEL and VRTX →Choose a stock to compare with RCEL →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own RCEL, latest filings →Back to the 13F Explorer →